Circulating biomarkers of hypertrophy and fibrosis in patients with hypertrophic cardiomyopathy assessed by cardiac magnetic resonance

References

• Anand, I.S., et al., 2010. Serial measurement of growth-differentiation factor-15 in heart failure: relation to disease severity and prognosis in the Valsartan Heart Failure Trial. Circulation, 122, 1387–1395.
   PubMed Web of Science ®Google Scholar
• Bruder, O., et al., 2010. Myocardial scar visualized by cardiovascular magnetic resonance imaging predicts major adverse events in patients with hypertrophic cardiomyopathy. Journal of the American college of cardiology, 56, 875–887.
   PubMed Web of Science ®Google Scholar
• Chan, R.H., et al., 2014. Prognostic value of quantitative contrast-enhanced cardiovascular magnetic resonance for the evaluation of sudden death risk in patients with hypertrophic cardiomyopathy. Circulation, 130, 484–495.
   PubMed Web of Science ®Google Scholar
• Coats, C.J., et al., 2013. Relation between serum N-terminal pro-brain natriuretic peptide and prognosis in patients with hypertrophic cardiomyopathy. European heart journal, 34, 2529–2537.
   PubMed Web of Science ®Google Scholar
• Cramer, G., et al., 2014. Relation of highly sensitive cardiac troponin T in hypertrophic cardiomyopathy to left ventricular mass and cardiovascular risk. American journal of cardiology, 113, 1240–1245.
   PubMed Web of Science ®Google Scholar
• D’Amato, R., et al., 2013. Prognostic value of N-terminal pro-brain natriuretic peptide in outpatients with hypertrophic cardiomyopathy. American journal of cardiology, 112, 1190–1196.
   PubMed Web of Science ®Google Scholar
• Elliott, P.M., et al., 2014. ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). European heart journal, 35, 2733–2779.
   PubMed Web of Science ®Google Scholar
• Gawor, M., et al., 2017. The usefulness of soluble ST2 and galectin-3 as novel biomarkers for better risk stratification in hypertrophic cardiomyopathy. Kardiologia polska, 75, 997–1004.
   PubMed Web of Science ®Google Scholar
• Gommans, D.F., et al., 2017. High T2-weighted signal intensity is associated with elevated troponin T in hypertrophic cardiomyopathy. Heart, 103, 293–299.
   PubMed Web of Science ®Google Scholar
• Harrigan, C.J., et al., 2011. Hypertrophic cardiomyopathy: quantification of late gadolinium enhancement with contrast-enhanced cardiovascular MR imaging. Radiology, 258, 128–133.
   PubMed Web of Science ®Google Scholar
• Heger, J., et al., 2010. Growth differentiation factor 15 acts anti-apoptotic and pro-hypertrophic in adult cardiomyocytes. Journal of cell physiology, 224, 120–126.
   PubMed Web of Science ®Google Scholar
• Hen, Y., et al., 2014. Prognostic value of late gadolinium enhancement on cardiac magnetic resonance imaging in Japanese hypertrophic cardiomyopathy patients. Circulation journal, 78, 929–937.
   PubMed Web of Science ®Google Scholar
• Ismail, T.F., et al., 2014. Role of late gadolinium enhancement cardiovascular magnetic resonance in the risk stratification of hypertrophic cardiomyopathy. Heart, 100, 1851–1858.
   PubMed Web of Science ®Google Scholar
• Kawasaki, T., et al., 2013. Usefulness of high-sensitivity cardiac troponin T and brain natriuretic peptide as biomarkers of myocardial fibrosis in patients with hypertrophic cardiomyopathy. American journal of cardiology, 112, 867–872.
   PubMed Web of Science ®Google Scholar
• Kłopotowski, M., et al., 2016. The value of cardiac magnetic resonance and distribution of late gadolinium enhancement for risk stratification of sudden cardiac death in patients with hypertrophic cardiomyopathy. Journal of cardiology, 68, 49–56.
   PubMed Web of Science ®Google Scholar
• Kubo, T., et al., 2013. Significance of high-sensitivity cardiac troponin T in hypertrophic cardiomyopathy. Journal of the American college of cardiology, 62, 1252–1259.
   PubMed Web of Science ®Google Scholar
• López, B., et al., 2015. Circulating biomarkers of myocardial fibrosis: the need for a reappraisal. Journal of the American college of cardiology, 65, 2449–2456.
   PubMed Web of Science ®Google Scholar
• Maron, M.S., 2013. Contrast-enhanced CMR in HCM: what lies behind the bright light of LGE and why it now matters. JACC cardiovascular imaging, 6, 597–599.
   PubMed Web of Science ®Google Scholar
• Meijers, W.C., et al., 2016. ST2 and galectin-3: ready for prime time? Electronic journal of the international federation of clinical chemistry, 27, 238–252.
   Google Scholar
• Montoro-García, S., et al., 2012. Growth differentiation factor-15, a novel biomarker related with disease severity in patients with hypertrophic cardiomyopathy. European journal of internal medicine, 23, 169–174.
   PubMed Web of Science ®Google Scholar
• Moravsky, G., et al., 2013. Myocardial fibrosis in hypertrophic cardiomyopathy: accurate reflection of histopathological findings by CMR. JACC cardiovascular imaging, 6, 587–596.
   PubMed Web of Science ®Google Scholar
• O’Hanlon, R., et al., 2010. Prognostic significance of myocardial fibrosis in hypertrophic cardiomyopathy. Journal of the American college of cardiology, 56, 867–874.
   PubMed Web of Science ®Google Scholar
• Park, J.R., et al., 2012. Degree and distribution of left ventricular hypertrophy as a determining factor for elevated natriuretic peptide levels in patients with hypertrophic cardiomyopathy: insights from cardiac magnetic resonance imaging. The international journal of cardiovascular imaging, 28, 763–772.
   PubMed Web of Science ®Google Scholar
• Rubinshtein, R., et al., 2010. Characteristics and clinical significance of late gadolinium enhancement by contrast-enhanced magnetic resonance imaging in patients with hypertrophic cardiomyopathy. Circulation heart failure, 3, 51–58.
   PubMed Web of Science ®Google Scholar
• Rudolph, A., et al., 2009. Noninvasive detection of fibrosis applying contrast-enhanced cardiac magnetic resonance in different forms of left ventricular hypertrophy relation to remodeling. Journal of the American college of cardiology, 53, 284–291.
   PubMed Web of Science ®Google Scholar
• Schmitter, D., et al., 2014. Clinical use of novel biomarkers in heart failure: towards personalized medicine. Heart failure reviews, 19, 369–381.
   PubMed Web of Science ®Google Scholar
• Śpiewak, M., et al., 2010. Comparison of different quantification methods of late gadolinium enhancement in patients with hypertrophic cardiomyopathy. European journal of radiology, 74, e149–e153.
   PubMed Web of Science ®Google Scholar
• Weng, Z., et al., 2016. Prognostic value of LGE-CMR in HCM: a meta-analysis. JACC cardiovascular imaging, 9, 1392–1402.
   PubMed Web of Science ®Google Scholar
• Xu, X., et al., 2011. Growth differentiation factor 15 in cardiovascular diseases: from bench to bedside. Biomarkers, 16, 466–475.
   PubMed Web of Science ®Google Scholar
• Yakar Tülüce, S., et al., 2016. Galectin-3 levels in patients with hypertrophic cardiomyopathy and its relationship with left ventricular mass index and function. Anatolian journal of cardiology, 16, 344–348.
   PubMed Web of Science ®Google Scholar
• Zhang, C., et al., 2016. Predictive values of N-terminal pro-B-type natriuretic peptide and cardiac troponin I for myocardial fibrosis in hypertrophic obstructive cardiomyopathy. PLoS One, 11, e0146572.
   PubMed Web of Science ®Google Scholar
• Zile, M.R. and Baicu, C.F., 2013. Biomarkers of diastolic dysfunction and myocardial fibrosis: application to heart failure with a preserved ejection fraction. Journal of cardiovascular translational research, 6, 501–515.
   PubMed Web of Science ®Google Scholar